cyclin-dependent kinase

(redirected from Cyclin-dependent kinases)
Also found in: Encyclopedia.

cyclin-dependent kinase (CDK)

a protein kinase that is activated by cyclin.

cyclin-dependent kinase

Abbreviation: CDK
A family of enzymes involved in regulation of the cell cycle. They serve as targets for pharmacological manipulation of this cycle, particularly during the unregulated proliferation of tumor cells.
See also: kinase
References in periodicals archive ?
For promoting cell cycle progression, cyclin D1 binds to cyclin-dependent kinase (CDK) 4/6 as the binding partners of cyclin D1 and subsequently phosphorylates and inactivates the retinoblastoma protein (Kato et al.
Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.
p27(KIP1) is a member of the CIP1/KIP1 family of cyclin-dependent kinase inhibitors and is a potential tumor suppressor gene.
5) suggest that genes up-regulated in parathyroid adenoma are those responsible for blood vessel angiogenesis and genes belonging to the cyclin-dependent kinase inhibitor groups.
Cyclin-dependent kinases (Cdks) are proteins that are involved in the regulation of the cell cycle.
p2lWafl/Cipl is an inhibitor of cyclin-dependent kinases involved in regulation of cell division and was the founding member of a family of functionally related kinase inhibitors (cycin-dependent kinase inhibitors; CKIs), now known to include p27, p28, p57, and DACAPO.
Dinaciclib is a pro-apoptotic inhibitor of cyclin-dependent kinases being evaluated by Merck for the potential treatment of cancer.
According to the company, Verzenio (abemaciclib) is an inhibitor of cyclin-dependent kinases (CDK)4 & 6, which are activated by binding to D-cyclins.
Five grants totaling more than $4 million in funding were awarded to support clinical research projects investigating IBRANCE (palbociclib), an oral, first-in-class inhibitor of cyclin-dependent kinases (CDKs) 4 and 6, in advanced breast cancer for 2015.
Results from Western blotting indicated that Gyp inhibited the protein levels of cyclin D1 and E, cyclin-dependent kinases cdk2 and cdk6 (Fig.
Sample topics include centrosomes in checkpoint responses, DNA damage response and the balance between cell survival and cell death, and targeting cyclin-dependent kinases with small molecule inhibitors.
1] During the cellular proliferative state, the complex of cyclin D1 and cyclin-dependent kinases phosphorylates the retinoblastoma protein, thereby releasing its inhibition on a transcriptional factor, E2F-1.

Full browser ?